Speaking in Paris at an artificial intelligence summit, the vice president gave an America First vision of the technology — ...

AKRON, OHIO / ACCESS Newswire / January 29, 2025 / ACU-Serve, a leader in healthcare revenue cycle optimization, is excited to announce the appointment of Sidney S. Simmons III (Sid) as its new ...

As Executive Vice President of Sales, Sid will oversee the company's dynamic sales team and lead initiatives to optimize and expand its sales operations. He is also being brought in to expand ...

The 47th president delivered a roughly 30-minute inaugural address after being sworn in at the U.S. Capitol Rotunda ... delivered a roughly 30-minute speech that outlined some of his policy ...

For decades, J.D. Power’s research has been a key tool for savvy consumers trying to separate companies with high-quality products and world-class customer service from the other guys.

Ben Simmons was once among the best players in the ... and it is without doubt the worst pain I've ever experienced It's also humiliating It's why I always will root for Simmons because I don ...

While the company's earnings beat was driven by its Innovative Medicines unit, mainly due to its multiple myeloma therapy, Darzalex, according to Bloomberg data on sales consensus, JNJ's MedTech ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

About 21 million U.S. adults in 2021 experienced at least one depressive episodes, latest government data shows. J&J said that about a third of adults will not respond to oral antidepressants alone.

Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder ...

With an FDA nod on Tuesday, Johnson & Johnson’s esketamine nasal spray Spravato became the industry’s first monotherapy approved for use in adults with treatment-resistant depression. The approval ...